Kayne Anderson Rudnick Investment Management
FATE icon

Kayne Anderson Rudnick Investment Management’s Fate Therapeutics FATE Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16
Closed -$1K – 628
2022
Q1 		$1K Buy
+16
New +$620 ﹤0.01% 628

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's FATE Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 16 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in FATE in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 16 Fate Therapeutics shares in Q2 2022, an estimated $1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Fate Therapeutics in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Fate Therapeutics position peaked at $1K in Q1 2022.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.